Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

Inclusion Criteria

• •Patients can participate in this study only if they meet all the following enrollment criteria:
• •1. Aged over 18 years, male, or female who is neither pregnant nor lactating;
• •2. Newly diagnosed acute myeloid leukemia (AML) with CEBPA mutation;
• •3. ECOG performance status ≤ Grade 3;
• •4. Capable of understanding and willing to participate in the study, and able to sign the informed consent form;
• •5. Patients are judged as "unfit" according to the Ferrara criteria. A patient is considered "unfit" if they meet at least one of the following criteria:
• •* Advanced age: \> 75 years old;
• •* Presence of severe underlying comorbidities involving the heart, lungs, kidneys, or liver; ③ Presence of active infection unresponsive to anti-infective treatment;
• •* Presence of cognitive impairment; ⑤ Poor performance status (persistent ECOG score ≥ Grade 3); ⑥ Other comorbidities judged by the investigator to make the patient unfit for intensive chemotherapy.